Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142753 · ClinicalTrials.gov registry record · Phase 4
Immunologic Memory (Supp. of ATN 024)
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 95
- Enrollment target
NCT00142753: Completed Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
NCT00142753 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 95 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142753, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 95 participants
- Enrollment target
Study Summary
This is an exploratory, laboratory-based evaluation of cellular immune response to immunization with hepatitis B surface antigen in HIV-infected and HIV-uninfected adolescents. This is a substudy of ATN 024 and ATN 025. This substudy will compare cellular immune response in responders and nonresponders to immunization and also evaluate the relationship of these factors to the persistence of known correlates of serologic protection for the hepatitis B virus.
Interventions
- BIOLOGICAL Engerix B
- BIOLOGICAL Twinrix for ATN 024
- BIOLOGICAL Recombivax
- BIOLOGICAL Twinrix for ATN 025
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
What the finished NCT00142753 record still lists
NCT00142753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 4 interventions - of which Engerix B is the first listed.
NCT00142753 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00142753 about?
NCT00142753 is a clinical study titled "Immunologic Memory (Supp. of ATN 024)". This is an exploratory, laboratory-based evaluation of cellular immune response to immunization with hepatitis B surface antigen in HIV-infected and HIV-uninfected adolescents. This is a substudy of ATN 024 and ATN 025. This substudy will compare cellular immune response in responders and nonrespond...
What is the current status of trial NCT00142753?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2005-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00142753?
The interventions under investigation include: Engerix B (BIOLOGICAL), Twinrix for ATN 024 (BIOLOGICAL), Recombivax (BIOLOGICAL), Twinrix for ATN 025 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00142753?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00142753's enrollment target sits among peer trials
95 869th of 2000 higher than 1,130 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia